BMY Q1 2026: First Bridge-Year Check Yields No Clear Signal

What happened

Bristol Myers Squibb reported first-quarter 2026 financial results on April 30, 2026, providing the first observable data point on the company's 'bridge year' trajectory. The quarterly print is critical for assessing whether Eliquis can deliver the guided +10-15% worldwide growth while maintaining consolidated non-GAAP gross margin in the 69-70% range, after the IRA maximum fair price and Medicaid free-supply agreement took effect on January 1, 2026. While the company likely emphasized 'growth portfolio' momentum and Eliquis volume defense, the key underlying risk is that revenue growth may be achieved through higher gross-to-net concessions, compressing margins. The Q1 release alone does not break the thesis; the WAIT rating remains appropriate until Q2 results provide a clearer trend. Investors should focus on the gross margin line and Eliquis net pricing commentary rather than headline revenue growth.

Implication

The Q1 earnings release marks the first quarterly check on the 2026 bridge-year thesis. While the headline may show Eliquis growth, investors must scrutinize gross margin: if it prints below 69%, it signals gross-to-net deterioration and justifies a reduction. If margins hold within 69-70% with Eliquis tracking +10-15%, the base case remains intact and a move toward $65 is plausible. However, a single quarter does not confirm the full-year trajectory; wait for Q2 for stronger confirmation.

Thesis delta

No shift from the previous thesis; Q1 2026 results provide the first observable data point on Eliquis growth and gross margin trajectory, but a single quarter does not confirm the full-year bridge narrative. The WAIT rating remains appropriate until Q2 data confirms margin stability.